T1	SectionAnnotate 0 11	SUBJECTIVE:
T2	SectionSkip 1923 1957	CURRENT MEDICATIONS:  See 
 intake
T3	SectionSkip 1961 1971	ALLERGIES:
T4	SectionAnnotate 2032 2047	FAMILY HISTORY:
T5	SectionAnnotate 2271 2286	SOCIAL HISTORY:
T6	SectionSkip 2969 4392	LABORATORY RESULTS:  Results for orders placed or performed during the hospital encounter of 05/28/16   Complete Blood Count with 5-part Differential   Result Value Ref Range    WBC Count 6.7 3.4 - 10 x10E9/L    RBC Count 3.89 (L) 4.4 - 5.9 x10E12/L    Hemoglobin 11.1 (L) 13.6 - 17.5 g/dL    Hematocrit 33.5 (L) 41 - 53 %    MCV 86 80 - 100 fL    MCH 28.5 26 - 34 pg    MCHC 33.1 31 - 36 g/dL    Platelet Count 203 140 - 450 x10E9/L    Neutrophil Absolute Count 4.06 1.8 - 6.8 x10E9/L    Lymphocyte Abs Cnt 1.49 1.0 - 3.4 x10E9/L    Monocyte Abs Count 0.84 (H) 0.2 - 0.8 x10E9/L    Eosinophil Abs Ct 0.23 0.0 - 0.4 x10E9/L    Basophil Abs Count 0.02 0.0 - 0.1 x10E9/L    Imm Gran, Left Shift 0.02 <0.1 x10E9/L   Urea Nitrogen, Serum / Plasma   Result Value Ref Range    Urea Nitrogen, Serum / Plasma 13 6 - 22 mg/dL   Creatinine, Serum / Plasma   Result Value Ref Range    Creatinine 1.06 0.61 - 1.24 mg/dL    eGFR if non-African 
 American 83 >60 mL/min    eGFR if African Amer 96 >60 mL/min   Aspartate Transaminase   Result Value Ref Range    Aspartate transaminase 20 17 - 42 U/L   Alanine Transaminase   Result Value Ref Range    Alanine transaminase 25 12 - 60 U/L   Bilirubin, Total   Result Value Ref Range    Bilirubin, Total 0.9 0.2 - 1.3 mg/dL   Alkaline Phosphatase   Result Value Ref Range    Alkaline Phosphatase 60 31 - 95 U/L   Cancer Antigen 19-9   Result Value Ref Range    Cancer Antigen 19-9 3 <36 U/mL
T7	SectionSkip 4399 4535	IMAGING:  Ct Abdomen /pelvis With Contrast    Result Date: 06/10/2016  CT ABDOMEN/PELVIS WITH CONTRAST  *****/*****/***** *****:***** PM
T8	SectionSkip 6036 7562	FINDINGS: Visualized lung bases:  For chest findings, please see the separately dictated report from the CT of the chest of the same date. Bones:  No suspicious lesions Liver:  6 mm hypervascular lesion in hepatic segment 8 which may reflect flash filling hemangioma or portosystemic shunt, unchanged from prior No significant intrahepatic biliary duct dilatation. Gallbladder:  Unremarkable Spleen:  Unremarkable Pancreas:  Redemonstration of ill-defined hypoattenuating mass centered in the pancreatic head, extending to the pancreatic tail, and involving the portosplenic confluence and superior mesenteric vein. Although difficult to measure this appears minimally increased in size and appears prior. Minimally decreased pancreatic duct dilatation to 7 mm in the pancreatic tail. The stent has been changed in courses from the common hepatic duct into the duodenum persistent pneumobilia suggests patency. Adrenal Glands:  Unremarkable Kidneys:  Unremarkable GI Tract:  No bowel obstruction. Pancreatic mass continues to abut the duodenum, unchanged from prior. Vasculature: No significant change in vascular involvement. Lymphadenopathy: Small mesenteric and retroperitoneal nodes, none of which are enlarged by size criteria. Ascites: Absent Bladder: Unremarkable Reproductive organs: Unremarkable Extraperitoneal soft tissues: Unremarkable     1.  Stable to minimally increased size of pancreatic mass compatible with known pancreatic adenocarcinoma. 2.  No evidence of metastatic disease in the abdomen/pelvis. END OF
T9	SectionAnnotate 7563 7574	IMPRESSION:
T10	SectionSkip 8948 9930	FINDINGS: LUNGS: Few new small nodules in the left lower lobe measuring up to 3 mm (series 2, images 121, 138, 166, 170) and a 7 mm new nodule in the lingula. Previously noted tiny nodule in the peripheral right upper lobe (prior study series 2, image 90) is not visualized on this exam. Right middle lobe nodule is unchanged (series 2, image 129). PLEURA: No pleural effusion. MEDIASTINUM: 8 mm lymph node adjacent to the inferior vena cava (previously 7 mm; series 2, image 179). No lymphadenopathy by size criteria. HEART/GREAT VESSELS: Normal heart size. No pericardial effusion. BONES/SOFT TISSUES: No suspicious lesions. VISIBLE ABDOMEN: Please see dedicated Abdomen and Pelvis CT report.     1.  5 new nodules measuring up to 7 mm in the lingula and left lower lobe. These are indeterminate 
 but are suspicious for metastases in the setting of known pancreatic adenocarcinoma. Attention on follow-up. 2.  No other definite evidence of metastatic disease in the chest. END OF
T11	SectionAnnotate 9949 9960	ASSESSMENT:
T12	PROBLEM 98 145	locally advanced adenocarcinoma of the pancreas
T13	PROBLEM 183 209	vague abdominal discomfort
T14	PROBLEM 218 238	some gross hematuria
T15	TEST 283 292	a CT scan
T16	PROBLEM 317 334	a pancreatic mass
T17	PROBLEM 336 349	His hematuria
T18	PROBLEM 378 393	renal lithiasis
T19	PROBLEM 442 461	biliary obstruction
T20	TEST 476 483	an ERCP
T21	TEST 489 495	an EUS
T22	TREATMENT 520 535	A plastic stent
T23	TEST 548 570	Fine-needle aspiration
T24	PROBLEM 574 582	the mass
T25	PROBLEM 592 606	adenocarcinoma
T26	PROBLEM 674 687	a lot of pain
T27	TREATMENT 709 720	gemcitabine
T28	TREATMENT 725 733	Abraxane
T29	TREATMENT 750 763	6 full cycles
T30	TEST 789 800	his CT scan
T31	PROBLEM 811 822	progression
T32	PROBLEM 902 920	pseudo-progression
T33	TREATMENT 925 948	His 5th cycle treatment
T34	PROBLEM 976 1002	biliary ductal obstruction
T35	TREATMENT 1011 1026	a plastic stent
T36	TREATMENT 1045 1069	an uncovered metal stent
T37	PROBLEM 1101 1117	pus and material
T38	TREATMENT 1146 1160	that procedure
T39	TREATMENT 1182 1184	IV
T40	TREATMENT 1189 1205	oral antibiotics
T41	TREATMENT 1213 1226	the procedure
T42	PROBLEM 1239 1272	intermittent abdominal discomfort
T43	TREATMENT 1302 1311	oxycodone
T44	PROBLEM 1402 1441	some numbness and tingling in his hands
T45	PROBLEM 1614 1625	his disease
T46	ClinicalCondition 1775 1787	Hypertension
T47	TREATMENT 1809 1848	his antihypertensive    PRIOR SURGERIES
T48	TREATMENT 1851 1859	Drainage
T49	PROBLEM 1863 1883	a perirectal abscess
T50	TREATMENT 1985 2003	Allergen Reactions
T51	TREATMENT 2008 2019	Penicillins
T52	PROBLEM 2061 2067	cancer
T53	PROBLEM 2150 2167	colorectal cancer
T54	PROBLEM 2221 2238	colorectal cancer
T55	TEST 2740 2746	Vitals
T56	TEST 2748 2750	BP
T57	TEST 2760 2765	Pulse
T58	TEST 2771 2775	Temp
T59	TEST 2781 2782	C
T60	TEST 2802 2806	Resp
T61	TEST 2812 2814	Ht
T62	TEST 2858 2860	Wt
T63	TEST 2880 2884	SpO2
T64	TEST 2892 2895	BMI
T65	PROBLEM 2956 2963	icterus
T66	TEST 3073 3093	Complete Blood Count
T67	TEST 3128 3133	Value
T68	TEST 3138 3143	Range
T69	TEST 3147 3150	WBC
T70	TEST 3151 3156	Count
T71	TEST 3170 3175	x10E9
T72	TEST 3181 3190	RBC Count
T73	TEST 3197 3198	L
T74	TEST 3222 3232	Hemoglobin
T75	TEST 3254 3258	g/dL
T76	TEST 3262 3272	Hematocrit
T77	TEST 3295 3298	MCV
T78	TEST 3317 3320	MCH
T79	TEST 3334 3336	pg
T80	TEST 3340 3344	MCHC
T81	TEST 3358 3362	g/dL
T82	TEST 3366 3380	Platelet Count
T83	TEST 3395 3400	x10E9
T84	TEST 3406 3416	Neutrophil
T85	TEST 3417 3425	Absolute
T86	TEST 3426 3431	Count
T87	TEST 3447 3452	x10E9
T88	TEST 3458 3472	Lymphocyte Abs
T89	TEST 3473 3476	Cnt
T90	TEST 3492 3497	x10E9
T91	TEST 3503 3515	Monocyte Abs
T92	TEST 3516 3521	Count
T93	TEST 3528 3529	H
T94	TEST 3541 3546	x10E9
T95	TEST 3552 3566	Eosinophil Abs
T96	TEST 3567 3569	Ct
T97	TEST 3585 3590	x10E9
T98	TEST 3596 3608	Basophil Abs
T99	TEST 3609 3614	Count
T100	TEST 3645 3649	Gran
T101	TEST 3651 3661	Left Shift
T102	TEST 3682 3695	Urea Nitrogen
T103	TEST 3697 3702	Serum
T104	TEST 3705 3720	Plasma   Result
T105	TEST 3721 3726	Value
T106	TEST 3727 3730	Ref
T107	TEST 3731 3736	Range
T108	TEST 3740 3744	Urea
T109	TEST 3745 3753	Nitrogen
T110	TEST 3755 3760	Serum
T111	TEST 3763 3769	Plasma
T112	TEST 3788 3798	Creatinine
T113	TEST 3800 3805	Serum
T114	TEST 3824 3829	Value
T115	TEST 3830 3833	Ref
T116	TEST 3834 3839	Range
T117	TEST 3843 3853	Creatinine
T118	TEST 3880 3884	eGFR
T119	TEST 3888 3910	non-African 
 American
T120	TEST 3928 3932	eGFR
T121	TEST 3936 3943	African
T122	TEST 3944 3948	Amer
T123	TEST 3965 3987	Aspartate Transaminase
T124	TEST 3997 4002	Value
T125	TEST 4016 4025	Aspartate
T126	TEST 4026 4038	transaminase
T127	TEST 4050 4053	U/L
T128	TEST 4056 4076	Alanine Transaminase
T129	TEST 4086 4091	Value
T130	TEST 4105 4125	Alanine transaminase
T131	TEST 4137 4152	U/L   Bilirubin
T132	TEST 4188 4197	Bilirubin
T133	TEST 4199 4204	Total
T134	TEST 4227 4247	Alkaline Phosphatase
T135	TEST 4257 4262	Value
T136	TEST 4276 4296	Alkaline Phosphatase
T137	TEST 4308 4328	U/L   Cancer Antigen
T138	TEST 4336 4348	Result Value
T139	TEST 4362 4368	Cancer
T140	TEST 4369 4376	Antigen
T141	TEST 4388 4406	U/mL       IMAGING
T142	TEST 4409 4441	Ct Abdomen /pelvis With Contrast
T143	TEST 4470 4472	CT
T144	TEST 4473 4501	ABDOMEN/PELVIS WITH CONTRAST
T145	PROBLEM 4576 4593	pancreatic cancer
T146	TEST 4618 4635	CT abdomen pelvis
T147	TEST 4648 4650	CT
T148	TEST 4744 4757	this CT study
T149	TREATMENT 4781 4815	DLP (mGy-cm) radiation dose values
T150	TEST 4886 4893	CTDIvol
T151	TEST 4902 4905	DLP
T152	TEST 4963 4970	CTDIvol
T153	TEST 4979 4982	DLP
T154	TEST 5093 5095	CT
T155	TEST 5100 5141	the volume Computed Tomography Dose Index
T156	TEST 5311 5345	the CT scanner acquisition factors
T157	TREATMENT 5529 5543	radiation dose
T158	TEST 5608 5626	Biomedical Imaging
T159	TEST 5672 5695	Computed Tomography (CT
T160	TEST 5820 5865	contiguous 1.25-mm collimation axial 
 images
T161	TEST 5958 5983	oral and rectal  contrast
T162	TEST 5985 6015	Coronal and sagittal reformats
T163	TEST 6074 6088	chest findings
T164	TEST 6137 6156	the CT of the chest
T165	PROBLEM 6186 6204	suspicious lesions
T166	PROBLEM 6213 6259	6 mm hypervascular lesion in hepatic segment 8
T167	PROBLEM 6278 6302	flash filling hemangioma
T168	TREATMENT 6306 6325	portosystemic shunt
T169	PROBLEM 6351 6399	significant intrahepatic biliary duct dilatation
T170	PROBLEM 6480 6512	ill-defined hypoattenuating mass
T171	PROBLEM 6695 6722	minimally increased in size
T172	PROBLEM 6742 6788	Minimally decreased pancreatic duct dilatation
T173	TREATMENT 6821 6830	The stent
T174	PROBLEM 6906 6928	persistent pneumobilia
T175	PROBLEM 7014 7031	bowel obstruction
T176	PROBLEM 7033 7048	Pancreatic mass
T177	PROBLEM 7119 7161	significant change in vascular involvement
T178	PROBLEM 7163 7178	Lymphadenopathy
T179	PROBLEM 7180 7222	Small mesenteric and retroperitoneal nodes
T180	PROBLEM 7269 7276	Ascites
T181	PROBLEM 7402 7445	minimally increased size of pancreatic mass
T182	PROBLEM 7462 7493	known pancreatic adenocarcinoma
T183	PROBLEM 7514 7554	metastatic disease in the abdomen/pelvis
T184	TEST 7579 7587	Ct Chest
T185	TEST 7630 7632	CT
T186	PROBLEM 7672 7688	Panceatic cancer
T187	TEST 7735 7780	Serial 1.25 mm axial images through the chest
T188	TREATMENT 7825 7845	intravenous contrast
T189	TEST 7940 7953	this CT study
T190	TREATMENT 7977 8011	DLP (mGy-cm) radiation dose values
T191	TEST 8082 8089	CTDIvol
T192	TEST 8098 8101	DLP
T193	TEST 8159 8166	CTDIvol
T194	TEST 8175 8178	DLP
T195	TEST 8289 8291	CT
T196	TEST 8296 8337	the volume Computed Tomography Dose Index
T197	TEST 8507 8541	the CT scanner acquisition factors
T198	TREATMENT 8725 8739	radiation dose
T199	TEST 8804 8822	Biomedical Imaging
T200	TEST 8868 8891	Computed Tomography (CT
T201	PROBLEM 8965 9009	Few new small nodules in the left lower lobe
T202	TEST 9042 9048	images
T203	PROBLEM 9073 9105	a 7 mm new nodule in the lingula
T204	PROBLEM 9124 9170	tiny nodule in the peripheral right upper lobe
T205	TEST 9172 9183	prior study
T206	TEST 9225 9234	this exam
T207	PROBLEM 9236 9260	Right middle lobe nodule
T208	PROBLEM 9308 9324	pleural effusion
T209	PROBLEM 9339 9354	8 mm lymph node
T210	PROBLEM 9433 9448	lymphadenopathy
T211	PROBLEM 9510 9530	pericardial effusion
T212	PROBLEM 9555 9573	suspicious lesions
T213	TEST 9603 9634	dedicated Abdomen and Pelvis CT
T214	PROBLEM 9651 9664	5 new nodules
T215	PROBLEM 9771 9781	metastases
T216	PROBLEM 9800 9831	known pancreatic adenocarcinoma
T217	PROBLEM 9891 9922	metastatic disease in the chest
T218	PROBLEM 9965 10012	Locally advanced adenocarcinoma of the pancreas
T219	PROBLEM 10028 10042	progression  2
T220	ClinicalCondition 10044 10056	Hypertension
T221	PROBLEM 10070 10092	cancer family syndrome
T222	PROBLEM 10117 10137	The new lung nodules
T223	TREATMENT 10226 10246	a chemotherapy break
T224	TREATMENT 10323 10335	this regimen
T225	PROBLEM 10356 10375	disease involvement
T226	Symptom 10392 10400	symptoms
T227	TEST 10441 10453	surveillance
T228	TREATMENT 10627 10637	management
T229	Age 39 41	47
T230	Histology 115 129	adenocarcinoma
T231	LocalInvasion 98 114	locally advanced
T232	Site 137 145	pancreas
R1	SiteOf Arg1:T232 Arg2:T230	
T233	ClinicalCondition 115 145	adenocarcinoma of the pancreas
A1	ChronicVal T233 chronic
T234	Symptom 189 209	abdominal discomfort
A2	IsPresentOnFirstCancerDiagnosis T234 yes
A3	IsCausedByDiagnosedCancer T234 yes
A4	ChronicVal T234 non-chronic
A5	ContinuityVal T234 new
T235	Symptom 223 238	gross hematuria
A6	IsPresentOnFirstCancerDiagnosis T235 yes
A7	IsCausedByDiagnosedCancer T235 no
A8	ChronicVal T235 non-chronic
A9	ContinuityVal T235 new
T236	Datetime 242 251	September
R2	HappensAtOnDuring Arg1:T236 Arg2:T235	
R3	HappensAtOnDuring Arg1:T236 Arg2:T234	
T237	Radiology 285 292	CT scan
A10	IntentVal T237 diagnosis
T238	RadPathResult 330 334	mass
A11	RadPathResultVal T238 InitialCancerDiagnosis
T239	Site 319 329	pancreatic
R4	SiteOf Arg1:T239 Arg2:T238	
R5	ResultOfTest Desc:T238 Test:T237	
T240	Symptom 340 349	hematuria
A12	IsPresentOnFirstCancerDiagnosis T240 yes
A13	IsCausedByDiagnosedCancer T240 no
A14	ChronicVal T240 non-chronic
A15	ContinuityVal T240 new
T241	ClinicalCondition 378 393	renal lithiasis
A16	ChronicVal T241 non-chronic
A17	ContinuityVal T241 stopped
R6	ConditionOrTreatmentCausesProblem Treatment:T241 Prob:T240	
T242	ClinicalCondition 442 461	biliary obstruction
A18	ChronicVal T242 non-chronic
A19	ContinuityVal T242 new
T243	Radiology 479 483	ERCP
A20	IntentVal T243 diagnosis
T244	Radiology 492 495	EUS
A21	IntentVal T244 diagnosis
T245	Datetime 508 518	October 24
R7	HappensAtOnDuring Arg1:T245 Arg2:T244	
R8	HappensAtOnDuring Arg1:T245 Arg2:T243	
R9	HappensBefore Arg1:T242 Arg2:T245	
T246	ProcedureName 522 535	plastic stent
A22	IntentVal T246 others
R10	HappensAtOnDuring Arg1:T245 Arg2:T246	
T247	ProcedureName 548 570	Fine-needle aspiration
A23	IntentVal T247 diagnosis
T248	RadPathResult 578 582	mass
A24	RadPathResultVal T248 InitialCancerDiagnosis
R11	ResultOfTest Desc:T248 Test:T244	
T249	RadPathResult 592 606	adenocarcinoma
A25	RadPathResultVal T249 InitialCancerDiagnosis
R12	ResultOfTest Desc:T249 Test:T247	
T250	Symptom 644 658	lost 43 pounds
A26	IsPresentOnFirstCancerDiagnosis T250 yes
A27	ChronicVal T250 non-chronic
A28	ContinuityVal T250 unclear
T251	Symptom 683 687	pain
A29	IsPresentOnFirstCancerDiagnosis T251 yes
A30	ChronicVal T251 non-chronic
A31	ContinuityVal T251 unclear
T252	MedicationRegimen 709 733	gemcitabine and Abraxane
A32	IsPresentOnFirstCancerDiagnosis T252 yes
A33	ChronicVal T252 non-chronic
A34	ContinuityVal T252 unclear
A35	TreatmentContinuityVal T252 started
A36	TreatmentTypeVal T252 maintenance
A37	TreatmentIntentVal T252 unclear
T253	Cycles 750 751	6
R13	TreatmentDesc Therapy:T253 Desc:T252	
T254	Cycles 779 780	2
R14	TreatmentDesc Therapy:T254 Desc:T252	
T255	Radiology 793 800	CT scan
A38	IntentVal T255 TreatmentAssessment
T256	DiseaseState 811 822	progression
A39	NegationModalityVal T256 uncertain_in_present
R15	TestOrProcedureReveals Test:T255 Desc:T256	
T257	DiseaseState 902 920	pseudo-progression
A40	NegationModalityVal T257 uncertain_in_present
T258	Cycles 929 932	5th
T259	ClinicalCondition 976 1002	biliary ductal obstruction
A41	ChronicVal T259 non-chronic
A42	ContinuityVal T259 new
T260	ProcedureName 1013 1039;1048 1069	plastic stent was replaced uncovered metal stent
A43	IntentVal T260 others
A44	TreatmentTypeVal T260 others
A45	TreatmentCategory T260 Others
R16	TestOrProcedureConductedForProblem Test:T260 Prob:T259	
T261	Symptom 1101 1117	pus and material
A46	IsPresentOnFirstCancerDiagnosis T261 no
A47	IsCausedByDiagnosedCancer T261 no
A48	ChronicVal T261 non-chronic
A49	ContinuityVal T261 stopped
R17	ConditionOrTreatmentCausesProblem Treatment:T260 Prob:T261	
T262	TreatmentType 1182 1205	IV and oral antibiotics
A50	TreatmentTypeVal T262 others
A51	TreatmentIntentVal T262 others
R18	TreatmentAdministeredForProblem Treatment:T262 Prob:T261	
T265	Symptom 1252 1272	abdominal discomfort
A58	IsPresentOnFirstCancerDiagnosis T265 no
A59	IsCausedByDiagnosedCancer T265 no
A60	ContinuityVal T265 new
T266	MedicationName 1302 1311	oxycodone
A61	TreatmentContinuityVal T266 continuing
A62	TreatmentTypeVal T266 others
A63	TreatmentIntentVal T266 others
A64	TreatmentCategory T266 Supportive
R20	TreatmentAdministeredForProblem Treatment:T266 Prob:T265	
T267	Symptom 1335 1343	appetite
A65	IsPresentOnFirstCancerDiagnosis T267 yes
A66	IsCausedByDiagnosedCancer T267 yes
A67	ChronicVal T267 non-chronic
A68	ContinuityVal T267 improving
T268	Symptom 1363 1378	gained kilogram
A69	ContinuityVal T268 improving
T269	Symptom 1407 1441	numbness and tingling in his hands
A70	IsPresentOnFirstCancerDiagnosis T269 no
A71	IsCausedByDiagnosedCancer T269 no
A72	ChronicVal T269 non-chronic
A73	ContinuityVal T269 new
R21	ConditionOrTreatmentCausesProblem Treatment:T252 Prob:T269	
T270	Symptom 1499 1522	regular bowel movements
A74	NegationModalityVal T270 negated
T271	Symptom 1591 1608	difficulty coping
A75	IsPresentOnFirstCancerDiagnosis T271 no
A76	IsCausedByDiagnosedCancer T271 yes
A77	ChronicVal T271 non-chronic
A78	ContinuityVal T271 new
T272	SDoH 1640 1666	social and economic issues
A79	IsStoppedOrContinuing T272 continuing
T273	Datetime 1715 1723	April 27
T274	SDoH 1702 1711	baby girl
A80	ChronicVal T46 chronic
A81	ContinuityVal T46 stable
T275	TreatmentType 1813 1829	antihypertensive
A82	TreatmentContinuityVal T275 discontinued_early
A83	TreatmentTypeVal T275 others
A84	TreatmentIntentVal T275 others
R22	TreatmentAdministeredForProblem Treatment:T275 Prob:T46	
T276	ProcedureName 1851 1859	Drainage
A85	IntentVal T276 others
A86	TreatmentTypeVal T276 others
A87	TreatmentCategory T276 Others
T277	ClinicalCondition 1876 1883	abscess
A88	ChronicVal T277 non-chronic
A89	ContinuityVal T277 stopped
T278	Site 1865 1875	perirectal
R23	SiteOf Arg1:T278 Arg2:T277	
R24	TestOrProcedureConductedForProblem Test:T276 Prob:T277	
T279	Age 1889 1891	17
T280	SectionSkip 1923 1948;1951 1957	CURRENT MEDICATIONS:  See intake
A90	SectionSkipType T280 medications
T281	SectionSkip 1961 2025	ALLERGIES:  Allergies   Allergen Reactions    Penicillins Hives
A91	SectionSkipType T281 allergies
T282	ClinicalCondition 2061 2067	cancer
A92	NegationModalityVal T282 negated
A93	ExperiencerVal T282 family
T283	PatientCharacteristics 2109 2119	2 siblings
T284	ClinicalCondition 2150 2167	colorectal cancer
A94	ChronicVal T284 chronic
A95	ExperiencerVal T284 family
T285	Age 2185 2187	55
T286	ClinicalCondition 2221 2238	colorectal cancer
A96	ExperiencerVal T286 family
T287	SectionSkip 2723 2963	PE:    Vitals:   Vitals: BP 131/90 | Pulse 64 | Temp 36.9 C (98.5 F) (Oral)  | Resp 20 | Ht 182 cm (5' 11.65") Comment: October 2015 | Wt 94.3 kg (208 lb) | SpO2 100% | BMI 28.48 kg/m2   In general, he appears comfortable.  HEENT no icterus
A97	SectionSkipType T287 physical_exam
T288	SectionSkip 2969 3899;3902 4387	LABORATORY RESULTS:  Results for orders placed or performed during the hospital encounter of 05/28/16   Complete Blood Count with 5-part Differential   Result Value Ref Range    WBC Count 6.7 3.4 - 10 x10E9/L    RBC Count 3.89 (L) 4.4 - 5.9 x10E12/L    Hemoglobin 11.1 (L) 13.6 - 17.5 g/dL    Hematocrit 33.5 (L) 41 - 53 %    MCV 86 80 - 100 fL    MCH 28.5 26 - 34 pg    MCHC 33.1 31 - 36 g/dL    Platelet Count 203 140 - 450 x10E9/L    Neutrophil Absolute Count 4.06 1.8 - 6.8 x10E9/L    Lymphocyte Abs Cnt 1.49 1.0 - 3.4 x10E9/L    Monocyte Abs Count 0.84 (H) 0.2 - 0.8 x10E9/L    Eosinophil Abs Ct 0.23 0.0 - 0.4 x10E9/L    Basophil Abs Count 0.02 0.0 - 0.1 x10E9/L    Imm Gran, Left Shift 0.02 <0.1 x10E9/L   Urea Nitrogen, Serum / Plasma   Result Value Ref Range    Urea Nitrogen, Serum / Plasma 13 6 - 22 mg/dL   Creatinine, Serum / Plasma   Result Value Ref Range    Creatinine 1.06 0.61 - 1.24 mg/dL    eGFR if non-African American 83 >60 mL/min    eGFR if African Amer 96 >60 mL/min   Aspartate Transaminase   Result Value Ref Range    Aspartate transaminase 20 17 - 42 U/L   Alanine Transaminase   Result Value Ref Range    Alanine transaminase 25 12 - 60 U/L   Bilirubin, Total   Result Value Ref Range    Bilirubin, Total 0.9 0.2 - 1.3 mg/dL   Alkaline Phosphatase   Result Value Ref Range    Alkaline Phosphatase 60 31 - 95 U/L   Cancer Antigen 19-9   Result Value Ref Range    Cancer Antigen 19-9 3 <36
A98	SectionSkipType T288 laboratory
T289	SectionSkip 4388 5856;5859 7804;7807 9745;9748 9942	U/mL       IMAGING:  Ct Abdomen /pelvis With Contrast    Result Date: 06/10/2016  CT ABDOMEN/PELVIS WITH CONTRAST  *****/*****/***** *****:***** PM CLINICAL HISTORY: 48-year-old male with pancreatic cancer COMPARISON:  01/28/2016 CT abdomen pelvis, 03/18/2016 CT RADIATION DOSE INDICATORS: ***** ***** received 2 exposure event(s) (excluding scout) during this CT study. The CTDIvol (mGy) and DLP (mGy-cm) radiation dose values for each event are: Event: 1;  anatomic area: Chest;  phantom: body;  CTDIvol: 14.2;  DLP: 533.3 Event: 2;  anatomic area: Chest;  phantom: body;  CTDIvol: 18.8;  DLP: 888.6 The following accession numbers are related to this dose report [*****]: ***** The dose indicators for CT are the volume Computed Tomography Dose Index (CTDIvol) and the Dose Length Product (DLP), and are measured in units of mGy and mGy-cm, respectively. These indicators are not patient dose, but values generated from the CT scanner acquisition factors.  Individual patient doses calculated from these values will depend on patient size and can substantially underestimate or overestimate the actual dose. For additional information on radiation dose, safety, and protection in the UCSF Department of Radiology and Biomedical Imaging, please refer to one of our FAQ leaflets on "Computed Tomography (CT)" or go to *****://*****.*****.*****.*****/*****/*****. TECHNIQUE: Following the administration of 150 cc of Omnipaque 350, contiguous 1.25-mm collimation axial images were obtained through the abdomen and pelvis. The gastrointestinal tract was opacified with oral and rectal  contrast. Coronal and sagittal reformats were also obtained. FINDINGS: Visualized lung bases:  For chest findings, please see the separately dictated report from the CT of the chest of the same date. Bones:  No suspicious lesions Liver:  6 mm hypervascular lesion in hepatic segment 8 which may reflect flash filling hemangioma or portosystemic shunt, unchanged from prior No significant intrahepatic biliary duct dilatation. Gallbladder:  Unremarkable Spleen:  Unremarkable Pancreas:  Redemonstration of ill-defined hypoattenuating mass centered in the pancreatic head, extending to the pancreatic tail, and involving the portosplenic confluence and superior mesenteric vein. Although difficult to measure this appears minimally increased in size and appears prior. Minimally decreased pancreatic duct dilatation to 7 mm in the pancreatic tail. The stent has been changed in courses from the common hepatic duct into the duodenum persistent pneumobilia suggests patency. Adrenal Glands:  Unremarkable Kidneys:  Unremarkable GI Tract:  No bowel obstruction. Pancreatic mass continues to abut the duodenum, unchanged from prior. Vasculature: No significant change in vascular involvement. Lymphadenopathy: Small mesenteric and retroperitoneal nodes, none of which are enlarged by size criteria. Ascites: Absent Bladder: Unremarkable Reproductive organs: Unremarkable Extraperitoneal soft tissues: Unremarkable     1.  Stable to minimally increased size of pancreatic mass compatible with known pancreatic adenocarcinoma. 2.  No evidence of metastatic disease in the abdomen/pelvis. END OF IMPRESSION:     Ct Chest With Contrast    Result Date: 06/10/2016  CT CHEST WITH CONTRAST CLINICAL HISTORY:  Panceatic cancer COMPARISON: 03/18/2016 and earlier TECHNIQUE: Serial 1.25 mm axial images through the chest were obtained after the administration of intravenous contrast. RADIATION DOSE INDICATORS: ***** ***** received 2 exposure event(s) (excluding scout) during this CT study. The CTDIvol (mGy) and DLP (mGy-cm) radiation dose values for each event are: Event: 1;  anatomic area: Chest;  phantom: body;  CTDIvol: 14.2;  DLP: 533.3 Event: 2;  anatomic area: Chest;  phantom: body;  CTDIvol: 18.8;  DLP: 888.6 The following accession numbers are related to this dose report [*****]: ***** The dose indicators for CT are the volume Computed Tomography Dose Index (CTDIvol) and the Dose Length Product (DLP), and are measured in units of mGy and mGy-cm, respectively. These indicators are not patient dose, but values generated from the CT scanner acquisition factors.  Individual patient doses calculated from these values will depend on patient size and can substantially underestimate or overestimate the actual dose. For additional information on radiation dose, safety, and protection in the UCSF Department of Radiology and Biomedical Imaging, please refer to one of our FAQ leaflets on "Computed Tomography (CT)" or go to *****://*****.*****.*****.*****/*****/*****. FINDINGS: LUNGS: Few new small nodules in the left lower lobe measuring up to 3 mm (series 2, images 121, 138, 166, 170) and a 7 mm new nodule in the lingula. Previously noted tiny nodule in the peripheral right upper lobe (prior study series 2, image 90) is not visualized on this exam. Right middle lobe nodule is unchanged (series 2, image 129). PLEURA: No pleural effusion. MEDIASTINUM: 8 mm lymph node adjacent to the inferior vena cava (previously 7 mm; series 2, image 179). No lymphadenopathy by size criteria. HEART/GREAT VESSELS: Normal heart size. No pericardial effusion. BONES/SOFT TISSUES: No suspicious lesions. VISIBLE ABDOMEN: Please see dedicated Abdomen and Pelvis CT report.     1.  5 new nodules measuring up to 7 mm in the lingula and left lower lobe. These are indeterminate but are suspicious for metastases in the setting of known pancreatic adenocarcinoma. Attention on follow-up. 2.  No other definite evidence of metastatic disease in the chest. END OF IMPRESSION:
A99	SectionSkipType T289 radiology_report
T290	ConsumptionQuantity 2306 2317	half a pack
T291	Tobacco 2321 2331	cigarettes
A100	IsStoppedOrContinuing T291 stopped
R25	ConsumptionQuantityRel Arg1:T290 Arg2:T291	
T292	Duration 2350 2357	4 years
R26	Temporal Arg1:T292 Arg2:T291	
T293	Datetime 2371 2375	2006
R27	EndsOnOrAt Arg1:T293 Arg2:T291	
T294	Alcohol 2405 2418	alcohol abuse
A101	IsStoppedOrContinuing T294 stopped
T295	ConsumptionQuantity 2442 2461	pint of tequila day
R28	ConsumptionQuantityRel Arg1:T295 Arg2:T294	
T296	Alcohol 2479 2515	drinking only socially more recently
A102	IsStoppedOrContinuing T296 continuing
T297	Drugs 2542 2554	heroin abuse
A103	IsStoppedOrContinuing T297 stopped
T298	Duration 2577 2590	several years
R29	HappensBefore Arg1:T298 Arg2:T297	
T299	Histology 9982 9996	adenocarcinoma
T301	LocalInvasion 9965 9981	Locally advanced
A104	EpisodeDescription T301 FirstOccurrence
T300	ClinicalCondition 9982 10012	adenocarcinoma of the pancreas
A105	ChronicVal T300 chronic
T302	DiseaseState 10028 10039	progression
A106	NegationModalityVal T302 uncertain_in_present
A107	ChronicVal T220 chronic
A108	ContinuityVal T220 stable
T303	ClinicalCondition 10070 10092	cancer family syndrome
A109	ChronicVal T303 chronic
A110	ContinuityVal T303 stable
T304	Metastasis 10121 10137	new lung nodules
A111	NegationModalityVal T304 uncertain_in_present
A112	EpisodeDescription T304 Progression
T305	TreatmentType 10228 10240	chemotherapy
A113	TreatmentContinuityVal T305 discontinued_early
A114	TreatmentTypeVal T305 maintenance
A115	TreatmentIntentVal T305 palliative
T306	TreatmentType 10328 10335	regimen
A116	TreatmentContinuityVal T306 discontinued_early
A117	TreatmentTypeVal T306 maintenance
A118	TreatmentIntentVal T306 palliative
A119	NegationModalityVal T226 negated
R30	ConditionOrTreatmentCausesProblem Treatment:T260 Prob:T265	
R19	BeginsOnOrAt Arg1:T273 Arg2:T274	
R31	HappensAtOnDuring Arg1:T276 Arg2:T279	
R32	BeginsOnOrAt Arg1:T284 Arg2:T285	
A52	DiseaseStateVal T302 progression-others
A53	DiseaseStateVal T257 progression-others
A54	DiseaseStateVal T256 progression-others
T263	ap_start 9949 9959	ASSESSMENT
T264	ap_end 10491 10501	follow-up.
T307	hpi_start 0 10	SUBJECTIVE
T308	hpi_end 1715 1724	April 27.
